Date: 2013-02-28
Type of information: Fundraising
Company: Dezima Pharma (The Netherlands)
Investors: Agentschap NL (The Netherlands) BioGeneration Ventures (The Netherlands) Forbion Capital Partners (The Netherlands) New Science Ventures (USA)
Amount: €14.2 million
Funding type: loan, series A financing round
Planned used: The funds will be used for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001(previously TA-8995) and to develop additional earlier-stage dyslipidemia assets.
Others: Dezima Pharma, a biotechnology company developing drugs in the field of dyslipidemia has raised a total of €14.2m ($18.6m ) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995) and to develop additional earlier-stage dyslipidemia assets. Last month, the company has announced the in-licensing of this product from Mitsubishi Tanabe Pharma Corporation (MTPC). The company plans to support clinical development of DEZ-001 to Phase 3 clinical trials.
Dezima has raised €9.8m in a Series A funding round, led by Forbion Capital Partners (NL) and BioGeneration Ventures (NL), with participation from New Science Ventures (USA). The Company has also been awarded a €4.4m loan (“Innovation Credit”) by Agentschap NL, an agency of the Dutch Ministry of Economic Affairs.
Marco Boorsma of Forbion Capital Partners, Somu Subramaniam of New Science Ventures, and Wil Hazenberg of BioGeneration Ventures will join the Board of Directors of Dezima Pharma.
Dezima Pharma was founded in 2012 by Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, The Netherlands, and seed-financed by Forbion Capital Partners and BioGeneration Ventures, to develop novel products to treat dyslipidemic patients suffering from cardiovascular disease.
Therapeutic area: Cardiovascular diseases - Metabolic diseases
